EC approves first-line ovarian cancer treatment
European Pharmaceutical Review
NOVEMBER 22, 2023
The small molecule treatment is indicated as a first-line maintenance treatment for individuals with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. ” The EC based its approval the Phase III ATHENA-MONO study results.
Let's personalize your content